A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2022-07-05
AEs
4
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-07-30 (study day 12); relationship: not assessed
moderate
assessed
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-08-07 (study day 20); relationship: N
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-09-11 (study day 55); relationship: N
mild
assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-10-29 (study day 103); relationship: N
Data queries
No data queries.